At this week's SNM meeting, PET developer Naviscan PET Systems of San Diego is highlighting clinical trial results that indicate that its PET mammography technology compares favorably to MRI in detecting breast cancer.
In a study of 136 patients using Naviscan's PEM Flex Solo II system, researchers found that PEM had a sensitivity of 91% in detecting ductal carcinoma in situ (DCIS) compared to 83% with MRI. PEM also showed better sensitivity than MRI in cancers smaller than 5 mm, and the system detected a 2-mm DCIS case that was negative on MRI, according to the company.
The research was presented by Dr. Kathy Schilling of the Center for Breast Care in Boca Raton, FL. Schilling has been studying PEM for more than two years, Naviscan said, and also is conducting a 400-patient multicenter trial comparing PEM with breast MRI that is scheduled to be completed this year.
Related Reading
Naviscan completes NY installation, May 21, 2008
Naviscan signs M. D. Anderson, April 3, 2008
Naviscan promotes Mirabella, February 5, 2008
Naviscan hires executives, January 8, 2008
Dilon, Naviscan settle patent dispute, December 21, 2007
Copyright © 2008 AuntMinnie.com
